Document Detail


PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity.
MedLine Citation:
PMID:  20226762     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oxidative stress has been shown to play an important role in the development of hypertensive renal injury. Peroxisome proliferator-activated receptors alpha (PPARalpha) has antioxidant effect. In this study, we demonstrated that fenofibrate significantly reduced proteinuria, inflammatory cell recruitment and extracellular matrix (ECM) proteins deposition in the kidney of SHRs without apparent effect on blood pressure. To investigate the mechanisms involved, we found that fenofibrate treatment markedly reduced oxidative stress accompanied by reduced activity of renal NAD(P)H oxidase, increased activity of Cu/Zn SOD, and decreased phosphorylation of p38MAPK and JNK in the kidney of SHRs. Taken together, fenofibrate treatment can protect against hypertensive renal injury without affecting blood pressure by inhibiting inflammation and fibrosis via suppression of oxidative stress and MAPK activity.
Authors:
Xiaoyang Hou; Ying H Shen; Chuanbao Li; Fei Wang; Cheng Zhang; Peili Bu; Yun Zhang
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-03-11
Journal Detail:
Title:  Biochemical and biophysical research communications     Volume:  394     ISSN:  1090-2104     ISO Abbreviation:  Biochem. Biophys. Res. Commun.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-12     Completed Date:  2010-05-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372516     Medline TA:  Biochem Biophys Res Commun     Country:  United States    
Other Details:
Languages:  eng     Pagination:  653-9     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Affiliation:
Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Shandong University Qilu Hospital, 250012 Jinan, Shandong, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antioxidants / therapeutic use*
Collagen / antagonists & inhibitors,  biosynthesis
Hypertension / complications*
Kidney Diseases / etiology,  prevention & control*
MAP Kinase Kinase 4 / antagonists & inhibitors
Male
Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors*
Oxidative Stress / drug effects*
PPAR alpha / agonists*
Procetofen / therapeutic use*
Rats
Rats, Inbred SHR
Superoxide Dismutase / metabolism
Transforming Growth Factor beta / biosynthesis
p38 Mitogen-Activated Protein Kinases
Chemical
Reg. No./Substance:
0/Antioxidants; 0/PPAR alpha; 0/Transforming Growth Factor beta; 49562-28-9/Procetofen; 9007-34-5/Collagen; EC 1.15.1.1/Superoxide Dismutase; EC 2.7.11.24/p38 Mitogen-Activated Protein Kinases; EC 2.7.12.2/MAP Kinase Kinase 4; EC 2.7.12.2/Mitogen-Activated Protein Kinase Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A miR-21 hairpin structure-based gene knockdown vector.
Next Document:  Novel Monoclonal Antibodies Recognizing the Active Conformation of Epidermal Growth Factor Receptor.